Connecticut Performs Poorly in Tobacco Control, Shows Latest Report

Regulations by 2FIRSTS.ai
Jan.25.2024
Connecticut Performs Poorly in Tobacco Control, Shows Latest Report
Connecticut's tobacco control efforts were deemed inadequate in a new report by the American Lung Association, citing poor funding and lack of flavor restrictions.

A recent report by the American Lung Association reveals that Connecticut has performed poorly in its efforts to eliminate tobacco use and enforce tobacco control laws. The report points out that the state has received failing grades for the eighth consecutive year in both tobacco prevention and cessation funding and flavored tobacco products.

 

Connecticut officials have announced an increase in spending on tobacco prevention, allocating a specific budget of $12 million annually towards aiding smoking cessation and curbing tobacco use. However, this funding falls short of the recommended amount by the Center for Disease Control and Prevention, undermining its effectiveness. Health officials lament that this has resulted in Connecticut receiving an 'F' grade in tobacco control, highlighting a notable disparity compared to other states.

 

A report is calling for an increase in national funding for tobacco control programs in order to more effectively address the challenges faced by states. The report also emphasizes the urgency of a statewide ban on flavored tobacco products. However, currently, no municipal government has taken the corresponding measures, and health officials have started discussions with local authorities and lawmakers to determine if progress can be made this year, though uncertainty remains.

 

Connecticut's cigarette tax has received a passing grade of B, making it one of the three highest cigarette taxes in the nation. This tax policy has been somewhat successful in helping to reduce the state's smoking rate by making people price-sensitive and consequently decreasing the consumption of traditional combustible cigarettes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris International U.S. White Paper: Misconceptions About Nicotine Among Medical Professionals, FDA Urged to Strengthen Public Education on “Smoke-Free Alternatives”
Philip Morris International U.S. White Paper: Misconceptions About Nicotine Among Medical Professionals, FDA Urged to Strengthen Public Education on “Smoke-Free Alternatives”
Philip Morris International’s U.S. affiliate (PMI America) has released a new white paper stating that U.S. healthcare professionals hold serious misconceptions about smoke-free products, with nearly half incorrectly believing that nicotine causes cancer. As a result, smokers are being denied scientifically accurate harm-reduction advice. The report calls on the U.S. Food and Drug Administration (FDA) to deliver accurate information on smoke-free alternatives to physicians, so they can help adul
Aug.19 by 2FIRSTS.ai
Brazilian city council of Anápolis approves new law banning the use of e-cigarettes and hookahs in public places
Brazilian city council of Anápolis approves new law banning the use of e-cigarettes and hookahs in public places
Anápolis city council approves ban on e-cigarettes and hookah in public places, awaiting Mayor Márcio Corrêa's signature.
Aug.13 by 2FIRSTS.ai
Greentank Technologies Appoints Chris Gemmell as Chief Product and Innovation Officer
Greentank Technologies Appoints Chris Gemmell as Chief Product and Innovation Officer
Greentank Technologies appoints Chris Gemmell as Chief Product & Innovation Officer, bringing extensive experience from tobacco industry.
Sep.04 by 2FIRSTS.ai
Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
The EU’s consultation on the Cardiovascular Health Plan, though not mentioning nicotine, has sparked debate over novel tobacco regulation. Advocates urge evidence-based recognition of harm reduction products, while opponents call for tighter rules. The plan may influence TPD III, drawing close scrutiny from both industry and health groups.
Sep.01
Although not yet approved by the FDA, Altria still plans to launch its new nicotine pouch product, on! PLUS™, in the U.S
Although not yet approved by the FDA, Altria still plans to launch its new nicotine pouch product, on! PLUS™, in the U.S
Altria announced that its subsidiary, Helix, will launch a new nicotine pouch product, on! PLUS™, in the U.S. this fall, with the initial markets covering North Carolina, Texas, and Florida. The product has not yet been approved by the FDA. It is noteworthy that the launch time and regions for on! PLUS™ are highly similar to those of BAT's planned disposable e-cigarette, Vuse One.
Aug.25
 KT&G Q2 earnings: net profit falls 54% to $103 million, NGP revenue down 0.8% to $141 million
KT&G Q2 earnings: net profit falls 54% to $103 million, NGP revenue down 0.8% to $141 million
KT&G has released its financial report for the second quarter and first half of 2025. The company's first-half revenue surpassed 3 trillion won (approximately US$2.16 billion) for the first time, with second-quarter revenue increasing by 8.7% year-over-year to US$1.114 billion. Net profit decreased by 54.1% year-over-year to US$103 million.
Aug.08 by 2FIRSTS.ai